Diclofenac sodium CAS 15307-79-6
Introduction：Basic information about Diclofenac sodium CAS 15307-79-6, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Diclofenac sodium Basic informationdescription Uses Mechanisms of action Clinical Application
| Product Name: | Diclofenac sodium |
| Synonyms: | N-(2,6-Dichlorophenyl)-o-aminophenylacetic acid sodium salt;sodium(o-((2,6-dichlorophenyl)amino)phenyl)acetate;sodium(o-(2,6-dichloroanilino)phenyl)acetate;sodiumdiclofenac;tsudohmin;AKOS B020028;2-(2,6-DICHLOROANILINO)PHENYLACETIC ACID SODIUM SALT;2-[(2,6-DICHLOROPHENYL)AMINO]-BENZENEACETIC ACID MONOSODIUM SALT |
| CAS: | 15307-79-6 |
| MF: | C14H10Cl2NNaO2 |
| MW: | 318.13 |
| EINECS: | 239-346-4 |
| Product Categories: | Other APIs;VOLATREN;Amines;Aromatics;Heterocycles;Organics;Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Lipid signaling;API's;15307-79-6 |
| Mol File: | 15307-79-6.mol |
Diclofenac sodium Chemical Properties
| Melting point | 288-290°C |
| density | 0.781 g/cm3 |
| storage temp. | room temp |
| solubility | H2O: 50 mg/mL |
| pka | 4(at 25℃) |
| form | White solid |
| color | White to Almost white |
| biological source | synthetic |
| Water Solubility | Soluble in water to 50mg/ml. |
| Merck | 14,3081 |
| BCS Class | 2 |
| Stability: | Stable. |
| Major Application | forensics and toxicology pharmaceutical (small molecule) |
| InChI | InChI=1S/C14H11Cl2NO2.Na/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1 |
| InChIKey | KPHWPUGNDIVLNH-UHFFFAOYSA-M |
| SMILES | C1(=CC=CC=C1CC([O-])=O)NC1=C(Cl)C=CC=C1Cl.[Na+] |
| CAS DataBase Reference | 15307-79-6(CAS DataBase Reference) |
Safety Information
| Hazard Codes | T,Xi |
| Risk Statements | 25-36/37/38-63 |
| Safety Statements | 22-36/37-45-36-26-60-20 |
| RIDADR | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | AG6330000 |
| HazardClass | 6.1(b) |
| PackingGroup | III |
| HS Code | 29224999 |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 toxic compounds or compounds which causing chronic effects |
| Hazard Classifications | Acute Tox. 3 Oral Aquatic Chronic 2 Repr. 2 STOT RE 1 |
| Toxicity | LD50 in mice, rats (mg/kg): ~390, 150 orally (Krupp) |
| description | Diclofenac Sodium (Diclofenac sodium) is the sodium salt form of diclofenac, a benzene acetic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic and anti-inflammatory activity. Diclofenac sodium is a non-selective reversible and competitive inhibitor of cyclooxygenase (COX), subsequently blocking the conversion of arachidonic acid into prostaglandin precursors. This leads to an inhibition of the formation of prostaglandins that are involved in pain, inflammation and fever. |
| Uses | Diclofenac is a phenylacetic acid derivative belonging to the class of the non-selective non-steroidal anti-inflammatory drugs (NSAIDs). It exhibits analgesic, antipyretic and anti-inflammatory activity. Due to its poor solubility, the parenteral formulation of diclofenac sodium (Voltarol ampoules) currently available in Europe contains the solvents propylene glycol and benzyl alcohol that allows intramuscular and intravenous administration. Diclofenac sodium has long been used to treat acute pain and inflammation, and is effective in various acute forms of pain. |
| Mechanisms of action | Putative mechanisms of action of diclofenac may include inhibition of leukotriene synthesis, inhibition of phospholipase A2, modulation of free arachidonic acid levels, stimulation of adenosine triphosphate-sensitive potassium channels via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and centrally mediated and neuropathic mechanisms. Other emerging mechanisms of action may include inhibition of peroxisome proliferator activated receptor-c, reduction in plasma and synovial substance P and interleukin-6 levels, inhibition of the thromboxane-prostanoid receptor and inhibition of acid-sensing ion channels. |
| Clinical Application | Clinical trials have demonstrated the analgesic efficacy of diclofenac sodium in terms of relieving moderate to severe postoperative pain in patients undergoing dental surgery or minor orthopaedic surgery. Subcutaneous diclofenac sodium also effectively relieved moderate to severe neuropathic pain, related to cancer or not. Diclofenac sodium was generally well tolerated in clinical trials, with injection-site reactions among the most commonly reported adverse events. |
| Description | Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC50s = 0.9-2.7 and 1.5-20 μM, for human COX-1 and COX-2, respectively). It is also an active metabolite of diclofenac methyl ester and diclofenac amide . Diclofenac inhibits release of arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) induced by A23187 in isolated rat peritoneal neutrophils and macrophages (IC50s = 60 and 10 μM, respectively). Transdermal administration of diclofenac inhibits carrageenan-induced paw edema in rats. Formulations containing diclofenac have been used in the treatment of pain associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. |
| Chemical Properties | Off-White Crystalline Solid |
| Originator | Voltaren,Fujisawa,Japan,1974 |
| History | Diclofenac sodium is a classic nonsteroidal anti-inflammatory drug (NSAID), known for its potent antipyretic, analgesic, and anti-inflammatory effects, and is marketed under brand names such as Voltaren. Its discovery and widespread use have had a profound impact on the treatment of pain and inflammation. Discovery and Patent (1965): Diclofenac sodium was synthesized by a team of researchers Rudolf Pfister and Alfred Sallmann at the Swiss pharmaceutical company Ciba-Geigy AG (now part of Novartis) while searching for a highly active and well-tolerated NSAID. The compound was patented in 1965. First Market Launch (1973): After extensive preclinical and clinical trials, diclofenac sodium was first marketed globally in 1973 under the brand name Voltaren. Its design philosophy is based on clear principles and aims to be an effective cyclooxygenase (COX) inhibitor. |
| Uses | Diclofenac sodium is a nonsteroidal anti-inflammatory compound and cyclooxygenase (COX) inhibitor. Oxidation of diclofenac sodium produces the metabolite 4'-hydroxy diclofenac) which demonstrates specific inhibition of Cox-2. Inhibition of Cox by diclofenac and 4'-hydroxy diclofenac suppresses prostaglandin E2 synthesis, producing anti-inflammatory and analgesic effects. Diclofenac is also shown to stabilize the native tetrameric conformation of transthyretin (TTR) fibrils, preventing the formation of insoluble amyloidogenic TTR deposits. Diclofenac Sodium is a substrate of CYP2C9. It is also used as an inhibitor of Cox-1 and Cox-2. |
| Definition | ChEBI: Diclofenac sodium is the sodium salt of diclofenac. It contains a diclofenac(1-). |
| Manufacturing Process | Four grams of N-chloroacetyl-N-phenyl-2,6-dichloroaniline and 4 grams ofaluminum chloride are well mixed together and heated for 2 hours at 160°C.The melt is cooled and poured onto about 50 grams of ice while it is stillwarm. The oil which separates is dissolved in 50 ml of chloroform, thechloroform solution is washed with 10 ml of water, dried over sodium sulfateand concentrated under 11 torr. The residue is distilled. The 1-(2,6-dichlorophenyl)-2-indolinone melts at 126°-127°C. A solution of 186 grams of 1-(2,6-dichlorophenyl)-2-indolinone in 660 ml ofethanol and 660 ml of 2 N sodium hydroxide solution is refluxed for 4 hours.The solution is then cooled and left to stand for 4 hours at 0°-5°C. Thecrystals which form are filtered off and recrystallized from water. The sodiumsalt of 2-(2,6-dichloroanilino)-phenylacetic acid melts at 283°-285°C. Theyield is 97% of theoretical, according to US Patent 3,558,690. |
| Brand name | Solaraze (Bioglan); Voltaren (Novartis);Aflamin;Alfamin;Allvoran;Artren;Blesin;B-voltaren;Cgp 9194;Chlorgyl;Ct-diclo;Dichloronic;Diclo attritin;Diclo spondril;Diclo-attritin;Diclo-burg;Diclo-phlohont;Diclo-puren;Diclo-recip;Dicloreum;Diclo-spondyril;Diclo-wolf;Dolobasan;Dolotrem;Doragon;Duravolten;Duvavotten;Feloran;Fenoflam;Flogofenac;Flogogenac;Forgenac;Inflamac;Klast;Monoflam;Myogit;Neuro-effekton;Neurofenac;Neuro-voltaren;Neviodin;Olfen;Panamor;Rewodina;Rheumalgen;Rheumavincin-n;Seecoren;Shignol;Silino;Sofarin;Thicataren;Toryxil;Tsudomin;Voltarene. |
| Therapeutic Function | Antiinflammatory |
| World Health Organization (WHO) | The World Health Organization currently has no information tosuggest that diclofenac is less safe than other widely available non-steroidalantiinflammatory substances of this type, or that children are particularly liable toreact adversely. It is registered in many countries in several dosage forms,including a 12.5 mg suppository indicated for juvenile arthritis. |
| General Description | Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Diclofenac is a derivative of benzeneacetic acid. It is categorized under the class of non-steroidal anti-inflammatory drugs (NSAIDs). It shows inflammatory, analgesic and antipyretic activities. |
| Biochem/physiol Actions | Standard NSAID and cyclooxygenase (COX) inhibitor. Major metabolites are 4′-hydroxydiclofenac and 5′-hydroxydiclofenac. Has been used as substrate selective for CYP2C9. |
| Clinical Use | Diclofenac sodium is indicated for the treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. |
| Side effects | The structure of diclofenac is a hybrid of a fenamate and an arylacetic acid. The compound isused as its sodium salt for the symptomatic reliefof rheumatoid arthritis and osteoarthritis, including degenerative joint disease of the hip. The recommended dose is 75 – 150 mg/d which is clinically equivalent to 3.6g/d of aspirin. Gastrointestinal problems (ulceration and bleeding) andadverse CNS reactions (dizziness and headache)are the most commonly encountered adverse effects. |
| Synthesis | Synthesis: Acylation of N-phenyl-2,6- dichloroaniline with chloroacetyl chloride gives the corresponding chloroacetanilide, which is fused with aluminum chloride to give 1-(2,6- dichlorophenyl)-2-indolinone. Hydrolysis of the indolinone with dilute aqueous-alcoholic sodium hydroxide affords the desired sodium salt directly. |
| Veterinary Drugs and Treatments | The equine topical cream (Surpass?) is labeled for the control ofpain and inflammation associated with osteoarthritis in tarsal, carpal,metacarpophalangeal, metarsophalangeal, and proximal interphalangeal(hock, knee, fetlock, pastern) joints for use up to 10 daysduration. While, theoretically, diclofenac could be used systemically(orally) in other veterinary species, there are approved and saferalternatives. |
| Drug interactions | Potentially hazardous interactions with other drugs antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia. Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage). Antibacterials: possibly increased risk of convulsions with quinolones; concentration reduced by rifampicin. Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban - avoid long term use with edoxaban; increased risk of haemorrhage with IV diclofenac - avoid. Antidepressants: increased risk of bleeding with SSRIs and venlaflaxine. Antidiabetic agents: effects of sulphonylureas enhanced. Antiepileptics: possibly increased phenytoin concentration. Ciclosporin: may potentiate nephrotoxicity; concentration increased by ciclosporin. Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib. |
| Metabolism | Diclofenac undergoes first-pass metabolism and is It is then excreted in the form of glucuronide and sulfate conjugates, mainly in the urine (about 60%) but also in the bile (about 35%).then extensively metabolised to 4′-hydroxydiclofenac, 5-hydroxydiclofenac, 3′-hydroxydiclofenac, and 4′,5-dihydroxydiclofenac by glucuronidation of the intact molecule or more commonly by single and multiple hydroxylation followed by glucuronidation. |
| storage | Store at RT |
| References | [1] Journal of Medicinal Chemistry, 1990, vol. 33, # 9, p. 2358 - 2368 [2] Patent: WO2010/69397, 2010, A1. Location in patent: Page/Page column 5 [3] Chemical and Pharmaceutical Bulletin, 1984, vol. 32, # 5, p. 1995 - 1997 [4] Patent: CN103145574, 2018, B. Location in patent: Paragraph 0036; 0037 |
Diclofenac sodium Preparation Products And Raw materials
| Raw materials | Ethanol-->Aniline-->Chloroacetyl chloride-->2-Chlorobenzoic acid-->2-Chlorotoluene-->2,6-Dichlorophenol-->2,5-Dichloroaniline-->2,6-Dichloroaniline-->Sodium hydroxide-->Aluminum chloride |
| Preparation Products | 1-(2,6-Dichlorophenyl)-2-hydroindole-->DICLOFENAC METHYL ESTER-->Oxindole |
